Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

334

Enrollment

OTHER

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)
Allergies

Interventions

DRUG: Omalizumab (Xolair®)
DRUG: Sodium Chloride (NaCl) 0.9 %

Sponsor

Johns Hopkins University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]